Condition: NHL · Multiple Myeloma · Blood Cancer · Sponsor: Indapta Therapeutics, INC.
This is an open label, Phase 1/2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combination with or without interleukin-2 (IL-2), and with or without isatuximab, daratumumab or rituximab to evaluate the safety, tolerability and preliminary antitumor activity in patients with advanced hematologic cancers.
This description comes directly from the study's public registry record.
Indapta Therapeutics, Inc. · TRIALS@INDAPTA.COM
Always discuss trial participation with your own doctor first.
| Valkyrie Clinical Trials | Los Angeles, California, United States | Recruiting |
| Florida Cancer Specialists and Research Institute - Lake Mary Cancer Center | Lake Mary, Florida, United States | Withdrawn |
| Emory University Hospital | Atlanta, Georgia, United States | Recruiting |
| University of Minnesota | Minneapolis, Minnesota, United States | Recruiting |
| NYP/Weill Cornell Medical Center | New York, New York, United States | Withdrawn |
| Atrium Health Wake Forest Baptist | Winston-Salem, North Carolina, United States | Recruiting |
| University Hospitals Cleveland | Cleveland, Ohio, United States | Recruiting |
| Providence Cancer Institute Franz Clinic | Portland, Oregon, United States | Withdrawn |
| Rhode Island Hospital | Providence, Rhode Island, United States | Recruiting |
| SCRI Oncology Partners | Nashville, Tennessee, United States | Recruiting |
| University of Texas MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| NEXT Oncology Virginia | Fairfax, Virginia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06119685